Related Experiment Video
Updated: Feb 7, 2026

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
Published on: December 17, 2021
Adalimumab in Active and Inactive, Non-Infectious Uveitis: Global Results from the VISUAL I and VISUAL II Trials
Hiroshi Goto1, Masahiro Zako2, Kenichi Namba3
1a Department of Ophthalmology , Tokyo Medical University , Tokyo , Japan.
Purpose:
Report global adalimumab safety and efficacy outcomes in patients with non-infectious uveitis.
Methods:
Adults with non-infectious intermediate, posterior, or panuveitis were randomized 1:1 to receive placebo or adalimumab in the VISUAL I (active uveitis) or VISUAL II (inactive uveitis) trials. Integrated global and Japan substudy results are reported. The primary endpoint was time to treatment failure (TF).
Results:
In the integrated studies, TF risk was significantly reduced (hazard ratio [95% CI]) with adalimumab versus placebo (VISUAL I: HR = 0.56 [0.40-0.76], p < 0.001; VISUAL II: HR = 0.52 [0.37-0.74], p < 0.001). In Japan substudies, no consistent trends were observed between groups (VISUAL I: HR = 1.20 [0.41-3.54]; VISUAL II: HR = 0.45 [0.20-1.03]). Adverse event rates were similar between treatment groups in both studies (854 to 1063 events/100 participant-years).
Conclusions:
Adalimumab lowered time to TF versus placebo in the integrated population; no consistent trends were observed in Japan substudies. Safety results were consistent between studies.
Related Concept Videos
Visual System
Once through the pupil, the light passes through the lens, a...
Visual Agnosia
Global Climate Change
Photoreceptors and Visual Pathways
Clinical Trials: Overview
Trial and Error and Algorithm

